Phase II, open-label study of HuM195 (humanized anti-CD33 monoclonal antibody) administered to patients with acute myelogenous leukemia (AML) who are documented regimen failures (RF) of the control arm of study 195-301

Trial Profile

Phase II, open-label study of HuM195 (humanized anti-CD33 monoclonal antibody) administered to patients with acute myelogenous leukemia (AML) who are documented regimen failures (RF) of the control arm of study 195-301

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2013

At a glance

  • Drugs Lintuzumab (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top